Home » Topics » Cancer, BioWorld Science

Cancer, BioWorld Science
RSS

Antiangiogenic gene therapy potentially useful for metastatic renal cell carcinoma

Feb. 22, 2008

Additional orphan drug status granted to Marshall Edwards' triphendiol

Feb. 21, 2008

Abiraterone active in phase I and II studies in castration-resistant prostate cancer

Feb. 21, 2008

Mixed results seen with PI-88-docetaxel in hormone-refractory prostate cancer

Feb. 21, 2008

Phase I study finds picoplatin plus docetaxel safe in hormone-refractory prostate cancer

Feb. 21, 2008

Phase II studies show promise of OGX-011 in prostate cancer

Feb. 21, 2008

Spectrum receives Canadian approval to initiate phase III trials of EOquin for bladder cancer

Feb. 21, 2008

FDA accepts NDA for Treanda in relapsed indolent non-Hodgkin's lymphoma

Feb. 20, 2008

Antitumor mechanism of marine lipopeptide elucidated

Feb. 20, 2008

Alligator Bioscience and ImmuRx enter into strategic collaboration

Feb. 20, 2008

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 2, 2026.
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
Amlogenyx’s AM-805 reduces amyloid plaques in AD
BioWorld Science
The potent carboxypeptidase enzyme protective protein cathepsin A (PPCA) is known to cleave the C-terminus of amyloid-β42, responsible for aggregation and...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 31, 2026
Atai Therapeutics patents new 5-HT2 receptor agonists
BioWorld Science
Atai Therapeutics Inc. has identified new 5-HT2 receptor agonists potentially useful for the treatment of psychiatric disorders.